Who Will Benefit from Adjuvant Chemoradiation Therapy in Patients with Locally Advanced Gastric Cancer Following D2 Dissection: Do N3 Patients Need Additional Radiation?
M. Fan,Z. Zhang
DOI: https://doi.org/10.1016/j.ijrobp.2015.07.531
2015-01-01
Abstract:Purpose/Objective(s)The role of adjuvant chemoradiation therapy (CRT) in locally advanced gastric cancer (LAGC) after D2 dissection is still controversial. The ARTIST trial failed to achieve disease-free survival (DFS) improvement from CRT compared to chemotherapy (CT) alone, but in subgroup analysis they discovered positive lymph node as a predictive factor for selective additional radiation; however, the majority of the patients enrolled in the study were relatively early-stage, limiting its application in the Chinese population where most LAGC patients were stage III. This retrospective study compared adjuvant CRT versus adjuvant chemotherapy (CT) after D2 dissection in patients with LAGC, and provided directions for patient selection.Materials/MethodsFour hundred twelve patients with LAGC (stage IB-IIIC) who underwent radical surgery (D2, R0) were retrospectively investigated. Patients were divided into two balanced groups based on clinical and pathological characteristics. Half of the patients (206) received adjuvant CRT, and the other half received adjuvant CT alone. Chemotherapies were fluorouracil-based regimens, and radiation was given 45 Gy (45-50.4 Gy) using 3D conformal or intensive modulation radiation therapy (IMRT) techniques. Concurrent chemotherapy was 5-fluorouracil 225 mg/m2/d weekly intravenously or capecitabine 625mg/m2/d BID d1-5 weekly.ResultsAfter a median follow-up of 39 (range, 3-92) months, of the 412 patients, 200 deaths were observed (93 in CRT group and 107 in CT group), and 212 experienced recurrence (92 in CRT group and 120 in CT group). Most of the patients (81.1%) were in stage III. The estimated 3-year DFS and overall survival (OS) in CRT and CT group was 49.5% versus 46.1% (P = .04), and 57.2% versus 52.9% (P = .18), respectively. The CT group had obviously increased risk of local regional recurrence compared to the CRT group (15.6% vs 8.7%, P = .01, respectively), while metastasis to peritoneal and distant organs were similar between the two groups (22.8% vs 20.3%, P = .39; 27.7% vs 22.3% P = .07, respectively). In subgroup analysis, male, over 60 years old, N1-2 were predictive factors for better survival from adjuvant CRT (HR = 1.48, 1.80, 1.72, respectively), while N3 patients failed to benefit from additional radiation. Multivariate analysis identified positive lymph nodes and receiving CRT as independent prognostic factors of DFS (HR = 0.40, P = .00; HR = 1.38, P = .02, respectively).ConclusionAdjuvant CRT could improve 3-year DFS and local control in patients of LAGC after D2 dissection. Male, over 60 years old, N1-2 were predictive factors for selective adjuvant CRT. Further studies should be focused on integrating clinical and molecular factors to identify targeted patients for selective adjuvant CRT. Purpose/Objective(s)The role of adjuvant chemoradiation therapy (CRT) in locally advanced gastric cancer (LAGC) after D2 dissection is still controversial. The ARTIST trial failed to achieve disease-free survival (DFS) improvement from CRT compared to chemotherapy (CT) alone, but in subgroup analysis they discovered positive lymph node as a predictive factor for selective additional radiation; however, the majority of the patients enrolled in the study were relatively early-stage, limiting its application in the Chinese population where most LAGC patients were stage III. This retrospective study compared adjuvant CRT versus adjuvant chemotherapy (CT) after D2 dissection in patients with LAGC, and provided directions for patient selection. The role of adjuvant chemoradiation therapy (CRT) in locally advanced gastric cancer (LAGC) after D2 dissection is still controversial. The ARTIST trial failed to achieve disease-free survival (DFS) improvement from CRT compared to chemotherapy (CT) alone, but in subgroup analysis they discovered positive lymph node as a predictive factor for selective additional radiation; however, the majority of the patients enrolled in the study were relatively early-stage, limiting its application in the Chinese population where most LAGC patients were stage III. This retrospective study compared adjuvant CRT versus adjuvant chemotherapy (CT) after D2 dissection in patients with LAGC, and provided directions for patient selection. Materials/MethodsFour hundred twelve patients with LAGC (stage IB-IIIC) who underwent radical surgery (D2, R0) were retrospectively investigated. Patients were divided into two balanced groups based on clinical and pathological characteristics. Half of the patients (206) received adjuvant CRT, and the other half received adjuvant CT alone. Chemotherapies were fluorouracil-based regimens, and radiation was given 45 Gy (45-50.4 Gy) using 3D conformal or intensive modulation radiation therapy (IMRT) techniques. Concurrent chemotherapy was 5-fluorouracil 225 mg/m2/d weekly intravenously or capecitabine 625mg/m2/d BID d1-5 weekly. Four hundred twelve patients with LAGC (stage IB-IIIC) who underwent radical surgery (D2, R0) were retrospectively investigated. Patients were divided into two balanced groups based on clinical and pathological characteristics. Half of the patients (206) received adjuvant CRT, and the other half received adjuvant CT alone. Chemotherapies were fluorouracil-based regimens, and radiation was given 45 Gy (45-50.4 Gy) using 3D conformal or intensive modulation radiation therapy (IMRT) techniques. Concurrent chemotherapy was 5-fluorouracil 225 mg/m2/d weekly intravenously or capecitabine 625mg/m2/d BID d1-5 weekly. ResultsAfter a median follow-up of 39 (range, 3-92) months, of the 412 patients, 200 deaths were observed (93 in CRT group and 107 in CT group), and 212 experienced recurrence (92 in CRT group and 120 in CT group). Most of the patients (81.1%) were in stage III. The estimated 3-year DFS and overall survival (OS) in CRT and CT group was 49.5% versus 46.1% (P = .04), and 57.2% versus 52.9% (P = .18), respectively. The CT group had obviously increased risk of local regional recurrence compared to the CRT group (15.6% vs 8.7%, P = .01, respectively), while metastasis to peritoneal and distant organs were similar between the two groups (22.8% vs 20.3%, P = .39; 27.7% vs 22.3% P = .07, respectively). In subgroup analysis, male, over 60 years old, N1-2 were predictive factors for better survival from adjuvant CRT (HR = 1.48, 1.80, 1.72, respectively), while N3 patients failed to benefit from additional radiation. Multivariate analysis identified positive lymph nodes and receiving CRT as independent prognostic factors of DFS (HR = 0.40, P = .00; HR = 1.38, P = .02, respectively). After a median follow-up of 39 (range, 3-92) months, of the 412 patients, 200 deaths were observed (93 in CRT group and 107 in CT group), and 212 experienced recurrence (92 in CRT group and 120 in CT group). Most of the patients (81.1%) were in stage III. The estimated 3-year DFS and overall survival (OS) in CRT and CT group was 49.5% versus 46.1% (P = .04), and 57.2% versus 52.9% (P = .18), respectively. The CT group had obviously increased risk of local regional recurrence compared to the CRT group (15.6% vs 8.7%, P = .01, respectively), while metastasis to peritoneal and distant organs were similar between the two groups (22.8% vs 20.3%, P = .39; 27.7% vs 22.3% P = .07, respectively). In subgroup analysis, male, over 60 years old, N1-2 were predictive factors for better survival from adjuvant CRT (HR = 1.48, 1.80, 1.72, respectively), while N3 patients failed to benefit from additional radiation. Multivariate analysis identified positive lymph nodes and receiving CRT as independent prognostic factors of DFS (HR = 0.40, P = .00; HR = 1.38, P = .02, respectively). ConclusionAdjuvant CRT could improve 3-year DFS and local control in patients of LAGC after D2 dissection. Male, over 60 years old, N1-2 were predictive factors for selective adjuvant CRT. Further studies should be focused on integrating clinical and molecular factors to identify targeted patients for selective adjuvant CRT. Adjuvant CRT could improve 3-year DFS and local control in patients of LAGC after D2 dissection. Male, over 60 years old, N1-2 were predictive factors for selective adjuvant CRT. Further studies should be focused on integrating clinical and molecular factors to identify targeted patients for selective adjuvant CRT.